{"component": "definition", "props": {"groups": [{"size": 6, "samples": [{"hash": "55kmprL1OWN", "uri": "/contracts/55kmprL1OWN#other-programs", "label": "Resource Adequacy Agreement", "score": 26.7289527721, "published": true}, {"hash": "1AQ8ek4EgzH", "uri": "/contracts/1AQ8ek4EgzH#other-programs", "label": "Resource Adequacy Agreement", "score": 26.3073237509, "published": true}, {"hash": "3qIpgrrLqAL", "uri": "/contracts/3qIpgrrLqAL#other-programs", "label": "Resource Adequacy Agreement", "score": 26.106091718, "published": true}], "snippet_links": [], "snippet": "has the meaning set forth in Section 4.1(f).", "hash": "ef0bae14cfdefb5c510775d87c4c9f82", "id": 1}, {"size": 5, "samples": [{"hash": "ahNMEhvveyK", "uri": "/contracts/ahNMEhvveyK#other-programs", "label": "Asset Contribution Agreement", "score": 31.340862423, "published": true}, {"hash": "h450L2Tlbf6", "uri": "/contracts/h450L2Tlbf6#other-programs", "label": "Asset Contribution Agreement (Maxygen Inc)", "score": 21.0, "published": true}, {"hash": "5vH2NTP21g9", "uri": "/contracts/5vH2NTP21g9#other-programs", "label": "Asset Contribution Agreement (Maxygen Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "by-or-on-behalf-of", "type": "definition", "offset": [71, 89]}, {"key": "directed-to", "type": "definition", "offset": [152, 163]}, {"key": "other-protein-variant", "type": "definition", "offset": [168, 189]}, {"key": "without-limitation", "type": "clause", "offset": [201, 219]}, {"key": "other-exploitation", "type": "clause", "offset": [308, 326]}, {"key": "other-protein-product", "type": "definition", "offset": [359, 380]}, {"key": "intended-for-use", "type": "definition", "offset": [381, 397]}, {"key": "in-the-field", "type": "clause", "offset": [398, 410]}], "snippet": "means, individually and collectively, any and all activities performed by or on behalf of Contributor, Company or any of their licensees or Affiliates, directed to any Other Protein Variant including, without limitation, activities for the discovery, research, development, manufacture, commercialization or other exploitation of any Other Protein Variant or Other Protein Product intended for use in the Field.", "hash": "c2e9459fde769d41b9965ee5742a5267", "id": 2}, {"size": 2, "samples": [{"hash": "6fUk6R4Lr75", "uri": "/contracts/6fUk6R4Lr75#other-programs", "label": "Technology License Agreement (Maxygen Inc)", "score": 21.0, "published": true}, {"hash": "2fIVgu14P5e", "uri": "/contracts/2fIVgu14P5e#other-programs", "label": "Technology License Agreement (Maxygen Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "asset-contribution-agreement", "type": "definition", "offset": [39, 67]}], "snippet": "shall have the meaning provided in the Asset Contribution Agreement.", "hash": "32475d899708294103ffa16311ffecb0", "id": 3}, {"size": 2, "samples": [{"hash": "csvyML3kZkW", "uri": "/contracts/csvyML3kZkW#other-programs", "label": "Employment Agreement (Clearway Energy LLC)", "score": 35.3271731691, "published": true}, {"hash": "20Sfyvp3Aej", "uri": "/contracts/20Sfyvp3Aej#other-programs", "label": "Employment Agreement (Clearway Energy, Inc.)", "score": 35.3271731691, "published": true}], "snippet_links": [], "snippet": "shall have the meaning set forth in Section 22 hereof.", "hash": "90bd08a8ec69d3fcf77f998336aea6c8", "id": 4}, {"size": 2, "samples": [{"hash": "5AQa82CxtYo", "uri": "/contracts/5AQa82CxtYo#other-programs", "label": "Other Products Collaboration Agreement (Maxygen Inc)", "score": 21.0, "published": true}, {"hash": "4a4vmTqYVdH", "uri": "http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTI2NjZ8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1", "label": "phx.corporate-ir.net", "score": 10.1704312115, "published": false}], "snippet_links": [{"key": "the-activities", "type": "clause", "offset": [53, 67]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [82, 100]}, {"key": "either-party", "type": "definition", "offset": [101, 113]}, {"key": "pursuant-to-the", "type": "clause", "offset": [114, 129]}, {"key": "preclinical-development-plan", "type": "definition", "offset": [130, 158]}, {"key": "directed-to", "type": "definition", "offset": [200, 211]}, {"key": "other-protein-variant", "type": "definition", "offset": [216, 237]}, {"key": "other-exploitation", "type": "clause", "offset": [314, 332]}, {"key": "other-product", "type": "definition", "offset": [365, 378]}, {"key": "in-the-field", "type": "clause", "offset": [387, 399]}, {"key": "during-the-term", "type": "clause", "offset": [400, 415]}], "snippet": "means, individually and collectively, any and all of the activities performed (i) by or on behalf of either Party pursuant to the Preclinical Development Plan or (ii) by or on behalf of CPC otherwise directed to any Other Protein Variant for the discovery, research, development, manufacture, commercialization or other exploitation of any Other Protein Variant or Other Product for use in the Field during the Term.", "hash": "6d6a2825a7155b3d497b1feebd644d99", "id": 5}, {"size": 2, "samples": [{"hash": "21jqhJHwbSo", "uri": "/contracts/21jqhJHwbSo#other-programs", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.9952087611, "published": true}, {"hash": "bWfZFtNszMb", "uri": "/contracts/bWfZFtNszMb#other-programs", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.7789185489, "published": true}], "snippet_links": [{"key": "the-definition-of", "type": "definition", "offset": [29, 46]}], "snippet": "has the meaning set forth in the definition of \u201cProgram\u201d.", "hash": "49863c38c0d80fbd359fa5919cf0c681", "id": 6}, {"size": 2, "samples": [{"hash": "21jqhJHwbSo", "uri": "/contracts/21jqhJHwbSo#other-programs", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.9952087611, "published": true}, {"hash": "bWfZFtNszMb", "uri": "/contracts/bWfZFtNszMb#other-programs", "label": "Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)", "score": 27.7789185489, "published": true}], "snippet_links": [{"key": "other-program", "type": "definition", "offset": [75, 88]}, {"key": "available-targets", "type": "definition", "offset": [93, 110]}, {"key": "the-foregoing", "type": "definition", "offset": [225, 238]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [250, 276]}, {"key": "lead-program", "type": "definition", "offset": [281, 293]}, {"key": "for-clarity", "type": "clause", "offset": [296, 307]}, {"key": "collaboration-target", "type": "definition", "offset": [420, 440]}, {"key": "subject-of", "type": "clause", "offset": [493, 503]}, {"key": "following-the", "type": "definition", "offset": [709, 722]}, {"key": "exercise-of-the-option", "type": "clause", "offset": [723, 745]}, {"key": "with-respect-to", "type": "clause", "offset": [746, 761]}, {"key": "development-commercialization-agreements", "type": "definition", "offset": [815, 857]}, {"key": "licensed-program", "type": "clause", "offset": [864, 880]}, {"key": "license-agreement", "type": "definition", "offset": [948, 965]}], "snippet": "means, collectively, the Macrophage Programs, B-Cell/Treg Programs and any other Program for Available Targets (excluding, in any event, the ICOS Activator Program and the PD-1 Activator Program); and \u201cPrograms\u201d means all of the foregoing (including for the avoidance of doubt the Lead Program). For clarity, each Program will only include Collaboration Candidates that are Immune Activators or Immune Suppressors, of a Collaboration Target, but not both, and if a Collaboration Target is the subject of both a Program for Immune Activating Collaboration Candidates and a Program for Immune Suppressing Collaboration Candidates, such Collaboration Target shall be a Collaboration Target of each such Program. Following the exercise of the Option with respect to a Program, such Program shall be referred to in such Development & Commercialization Agreements as a \u201cLicensed Program\u201d (where such Development & Commercialization Agreement is the PD-1 License Agreement), or a \u201cCo-Co Program\u201d (where such Development & Commercialization Agreement is a Co-Development and Co-Commercialization Agreement).", "hash": "09f37ab3a221b05bf4a5190394088f07", "id": 7}, {"size": 2, "samples": [{"hash": "ghe1XZbFgFd", "uri": "/contracts/ghe1XZbFgFd#other-programs", "label": "Master Joint Venture Agreement", "score": 31.340862423, "published": true}, {"hash": "kXQ6J0Rjij3", "uri": "/contracts/kXQ6J0Rjij3#other-programs", "label": "Joint Venture Agreement (Maxygen Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "asset-contribution-agreement", "type": "definition", "offset": [57, 85]}], "snippet": "has the meaning assigned to it in Section 1.40(b) of the Asset Contribution Agreement.", "hash": "28fc9c426c4b58ac2cce64384b3c6f1f", "id": 8}, {"size": 2, "samples": [{"hash": "hADV5GmzuxE", "uri": "/contracts/hADV5GmzuxE#other-programs", "label": "Employment Agreement (Tvi Corp)", "score": 21.0, "published": true}, {"hash": "hmuwEayXECz", "uri": "https://www.sec.gov/Archives/edgar/data/352079/000119312506219972/dex102.htm", "label": "Bonus Program (Tvi Corp)", "score": 7.0, "published": false}], "snippet_links": [{"key": "bonus-programs", "type": "definition", "offset": [24, 38]}, {"key": "the-definition-of", "type": "definition", "offset": [154, 171]}, {"key": "allocable-share", "type": "definition", "offset": [184, 199]}], "snippet": "means the two (2) other bonus programs established as of this date for the two other Signature Managers substantially identical to this Program excepting the definition of \u201cEmployee\u2019s Allocable Share.\u201d", "hash": "24e12bbfe9be28434bb75ef330566919", "id": 9}, {"size": 1, "samples": [{"hash": "janu2GLndmD", "uri": "/contracts/janu2GLndmD#other-programs", "label": "Asset Purchase Agreement (2seventy Bio, Inc.)", "score": 35.3518138261, "published": true}], "snippet_links": [{"key": "aml-program", "type": "definition", "offset": [39, 50]}], "snippet": "means the bbT369 Program, AID Program, AML Program, CRC-CART Program, and \u2587\u2587\u2587\u2587\u2587-33 Program.", "hash": "119160f073c357ebf5fa1b672b39d985", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXb3RoZXItcHJvZ3JhbXMjMDAwMDAwMGEMogECZW4YACAA", "definition": {"size": 26, "title": "Other Programs", "snippet": "has the meaning set forth in Section 4.1(f).", "id": "other-programs", "examples": ["<strong>Other Programs</strong> as Payers for Services \u2013 Non-Duplication of Payment The Contractor may not seek compensation from monies payable through this Contract for the costs of goods and services that may be or are reimbursed, in whole or in part, from <strong>other programs</strong> and sources.", "Title Certificated Classified Percent Funded by DSA Percent Funded by Other Program(s) Name of Other Program Funding Source # FTE # FTE Service Budget: Identify all costs related to providing the services (instructional and support) to run the service described.", "Evening School, <strong>Other Programs</strong>, Hourly-as- Needed, and Annual Program-Based Instructional Employees.", "If payment is made through the FTA Electronic Clearinghouse Operation (ECHO) using an ECHO Control Number, the Recipient agrees to comply with: FTA&#x27;s ECHO requirements that implement U.S. Department of Treasury (U.S. Treasury) Circular 1075, Part 205, &quot;Withdrawal of Cash from the Treasury for Advances Under Federal Grants and <strong>Other Programs</strong>;&quot; Treasury Financial Manual, Vol.", "Contributor has the full right to grant to Company the licenses (or sublicenses, as applicable) under the Licensed Intellectual Property Controlled by Contributor for the purpose of conducting the 4 Program and <strong>Other Programs</strong>, all as set forth in, and on the terms and conditions set forth in, the Technology License Agreement.", "Duration: 12 months Bonuses: Not applicable Eligibility: New Non-EU clients only O Commission on selected pairs (major and Gold) Offers / <strong>Other Programs</strong>: Cannot combine Unable to open a position with negative spread From 0 Spread on selected pairs (majors and GOLD) EA: Prohibited Swap: Up to 50% greater than Classic Account O withdrawal fees by credit card.", "All former employees and consultants of Contributor have entered in a valid and binding written agreement with Contributor sufficient to vest title in Contributor of all Contributor Intellectual Property used in the conduct of (i) the 4 Program and (ii) the <strong>Other Programs</strong> with respect to the proteins or polypeptides identified in Section 5.7(h) of the Contributor Disclosure Schedule, in each case, created by such employee or consultant in the scope of his or her services or employment for Contributor.", "In the event of any conflict between the terms of this Agreement and the terms of the <strong>Other Programs</strong> or any other contract, the terms of this Agreement will control.", "Sections 10.1(2) (Duty Uniform for Dual Status Technicians), 11.3(5) (Safety and Protective Clothing/Equipment), and 11.13(1) (<strong>Other Programs</strong>) notwithstanding, employees must wear their assigned duty uniform/attire at all times during the work shift.", "The parties note the government\u2019s intention, conditional upon the approval by the Lieutenant- Governor-in-Council, to enhance the funding benchmarks for the Continuing Education and the International Languages, Elementary components of the Continuing Education and <strong>Other Programs</strong> Grant in the GSN by 3.5% in 2009-2010."], "related": [["computer-programs", "Computer Programs", "Computer Programs"], ["third-party-payor-programs", "Third Party Payor Programs", "Third Party Payor Programs"], ["computer-program", "Computer program", "Computer program"], ["programs", "Programs", "Programs"], ["program", "Program", "Program"]], "related_snippets": [], "updated": "2025-07-06T21:56:50+00:00"}, "json": true, "cursor": ""}}